Sun Pharmaceutical Industries is looking to expand its specialty business across different regions like Greater China and Japan after having established presence in the US market. The company's strategy of developing the specialty business as an additional growth engine has started delivering results, with a gradual ramp up in specialty revenues. The company expects this momentum to continue over the next few years, although the COVID-19 pandemic and lockdowns may throw up some uncertainties in the near-term.
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
